Patients with advanced/metastatic NSCLC treated with prior platinum-based chemotherapy received escalating doses of weekly cetuximab ( 100 , 200 , and 250 mg/m ( 2 ) , IV ) and fixed doses of gefitinib ( 250 mg/d , PO ) until disease progression or unacceptable toxicity .
